News

23.05.2018 11:15

Keensight Capital invests in Biovian, a leading biopharmaceutical contract development and manufacturing organization (CDmO)

Keensight Capital, one of the leading players in Growth Private Equity, announced the acquisition of a majority stake in Biovian, a leading European player in contract manufacturing and development of biopharmaceuticals, alongside the founders and the managers.


To enable this next growth stage, Biovian receives a significant investment from Keensight Capital who will mobilize ample resources to help the management team to implement a strategic development plan to become a leading European CDMO and to support the Company to:


  • Increase capacities, both in the complex microbial development space and in the booming viral vector and gene therapy market,

  • Expand internationally

  • Further extend the one-stop-shop concept and reinforce its services portfolio to support its clients over additional stages of their products’ life cycle with “follow the molecule” approach.



Please see more information from press release:


Keensight Capital - Biovian - Press Release 20180523 (pdf)


pic1

Biovian responds to worldwide lack of Biopharmaceutical Process Development and Manufacturing capacity by accelerating growth plans and expanding Gene Therapy and microbial production facilities.








Return to headlines